331 related articles for article (PubMed ID: 29459361)
21. Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Bossard M; Granger CB; Tanguay JF; Montalescot G; Faxon DP; Jolly SS; Widimsky P; Niemela K; Steg PG; Natarajan MK; Gao P; Fox KAA; Yusuf S; Mehta SR
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29101117
[TBL] [Abstract][Full Text] [Related]
22. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
[TBL] [Abstract][Full Text] [Related]
23. Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial.
Yan AT; Roe MT; Neely M; Cyr DD; White H; Fox KAA; Prabhakaran D; Armstrong PW; Ohman EM; Goodman SG
Coron Artery Dis; 2018 Sep; 29(6):469-476. PubMed ID: 29652672
[TBL] [Abstract][Full Text] [Related]
24. Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome).
Fosbøl EL; Ju C; Anstrom KJ; Zettler ME; Messenger JC; Waksman R; Effron MB; Baker BA; Cohen DJ; Peterson ED; Wang TY
Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27789517
[TBL] [Abstract][Full Text] [Related]
25. Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Bae JP; Faries DE; Ernst FR; Lipkin C; Zhao Z; Moretz C; Lieu HD; Effron MB
Curr Med Res Opin; 2014 Nov; 30(11):2207-16. PubMed ID: 25034466
[TBL] [Abstract][Full Text] [Related]
26. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
[TBL] [Abstract][Full Text] [Related]
27. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
[TBL] [Abstract][Full Text] [Related]
28. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
[TBL] [Abstract][Full Text] [Related]
29. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Schüpke S; Neumann FJ; Menichelli M; Mayer K; Bernlochner I; Wöhrle J; Richardt G; Liebetrau C; Witzenbichler B; Antoniucci D; Akin I; Bott-Flügel L; Fischer M; Landmesser U; Katus HA; Sibbing D; Seyfarth M; Janisch M; Boncompagni D; Hilz R; Rottbauer W; Okrojek R; Möllmann H; Hochholzer W; Migliorini A; Cassese S; Mollo P; Xhepa E; Kufner S; Strehle A; Leggewie S; Allali A; Ndrepepa G; Schühlen H; Angiolillo DJ; Hamm CW; Hapfelmeier A; Tölg R; Trenk D; Schunkert H; Laugwitz KL; Kastrati A;
N Engl J Med; 2019 Oct; 381(16):1524-1534. PubMed ID: 31475799
[TBL] [Abstract][Full Text] [Related]
30. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
Jin C; Kim MH; Bang J; Serebruany V
Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
[TBL] [Abstract][Full Text] [Related]
31. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
Aradi D; Gross L; Trenk D; Geisler T; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Ruzsa Z; Ungi I; Rizas KD; May AE; Mügge A; Zeiher AM; Holdt L; Huber K; Neumann FJ; Koltowski L; Huczek Z; Hadamitzky M; Massberg S; Sibbing D
Eur Heart J; 2019 Jun; 40(24):1942-1951. PubMed ID: 31226213
[TBL] [Abstract][Full Text] [Related]
32. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
33. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
[TBL] [Abstract][Full Text] [Related]
35. Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study.
Baber U; Sartori S; Aquino M; Kini A; Kapadia S; Weiss S; Strauss C; Muhlestein JB; Toma C; Rao SV; DeFranco A; Poddar KL; Chandrasekhar J; Weintraub W; Henry TD; Bansilal S; Baker BA; Marrett E; Keller S; Effron M; Pocock S; Mehran R
Am Heart J; 2017 Jun; 188():73-81. PubMed ID: 28577683
[TBL] [Abstract][Full Text] [Related]
36. Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial.
Lahu S; Scalamogna M; Ndrepepa G; Menichelli M; Valina C; Hemetsberger R; Witzenbichler B; Bernlochner I; Joner M; Xhepa E; Hapfelmeier A; Kufner S; Sager HB; Mayer K; Kessler T; Laugwitz KL; Richardt G; Schunkert H; Neumann FJ; Kastrati A; Cassese S
J Am Heart Assoc; 2022 Dec; 11(24):e027257. PubMed ID: 36515247
[TBL] [Abstract][Full Text] [Related]
37. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.
Sibbing D; Gross L; Trenk D; Jacobshagen C; Geisler T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Parma R; Felix SB; Neumann FJ; Hausleiter J; Baylacher M; Koltowski L; Mehilli J; Huber K; Huczek Z; Aradi D; Massberg S;
Eur Heart J; 2018 Aug; 39(29):2749-2758. PubMed ID: 29912422
[TBL] [Abstract][Full Text] [Related]
38. Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial.
Menichelli M; Neumann FJ; Ndrepepa G; Mayer K; Wöhrle J; Bernlochner I; Richardt G; Witzenbichler B; Sibbing D; Gewalt S; Angiolillo DJ; Lahu S; Hamm CW; Hapfelmeier A; Trenk D; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
Ann Intern Med; 2020 Sep; 173(6):436-444. PubMed ID: 32687741
[TBL] [Abstract][Full Text] [Related]
39. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
